Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

4.98USD
11:57am EDT
Change (% chg)

$-0.17 (-3.30%)
Prev Close
$5.15
Open
$5.11
Day's High
$5.12
Day's Low
$4.91
Volume
80,667
Avg. Vol
223,772
52-wk High
$5.71
52-wk Low
$1.07

Select another date:

Wed, Sep 6 2017

Verastem's blood cancer drug succeeds in late-stage trial

Verastem Inc said on Wednesday its drug to treat some types of blood cancer met the main goal of a late-stage study, sending the U.S. drug developer's shares up as much as 44.5 percent.

UPDATE 2-Verastem's blood cancer drug succeeds in late-stage trial

* Drug could rake in >$400 mln within 5 yrs of launch -analyst

BRIEF-Verastem expands duvelisib development program to include peripheral T-cell lymphoma

* Verastem expands duvelisib development program to include peripheral T-cell lymphoma

RPT-Verastem's blood cancer drug succeeds in late-stage trial

Sept 6 Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

RPT-Verastem's blood cancer drug succeeds in late-stage trial

Sept 6 Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

BRIEF-Verastem announces positive top-line data from the pivotal phase 3 Duo study

* Verastem announces positive top-line data from the pivotal phase 3 Duo study in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Verastem's blood cancer drug succeeds in late-stage trial

Sept 6 Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

BRIEF-Ridgeback Capital Investments reports 7.7 pct passive stake in Verastem

* Ridgeback Capital Investments Lp reports a 7.7 percent passive stake in Verastem inc as of July 10, 2017 - sec filing Source text for Eikon: Further company coverage:

BRIEF-Verastem names Julie B. Feder as chief financial officer

* Verastem Inc - ‍feder joins Verastem from Clinton Health Access Initiative, Inc​ Source text for Eikon: Further company coverage:

BRIEF-Verastem director Barberich buys 30,000 shares of co's common stock on May 15

* Verastem Inc director Timothy Barberich reports purchase of 30,000 shares of co's common stock on May 15 at average price of $2.45 per share - SEC filing Source text: (http://bit.ly/2pKDBMW) Further company coverage:

Select another date: